脂蛋白(a)与复发性动脉粥样硬化心血管事件:美国Family Heart数据库研究
脂蛋白(a)水平越高,复发性ASCVD风险持续增加,该关联在性别和种族间一致,高强度降LDL-C治疗可能部分减轻脂蛋白(a)≥180 nmol/L的不良影响。
要点
- 脂蛋白(a)≥300 nmol/L者复发性ASCVD风险较<15 nmol/L者增加45%。
- 脂蛋白(a)与复发ASCVD风险的关联在性别和种族间无显著交互。
- 高强度降LDL-C治疗可能减轻脂蛋白(a)≥180 nmol/L的不良影响。
主要发现
- 与脂蛋白(a)<15 nmol/L相比,15-79 nmol/L的校正风险比为1.04(95%CI 1.01-1.07),80-179 nmol/L为1.15(1.12-1.19),180-299 nmol/L为1.29(1.25-1.33),≥300 nmol/L为1.45(1.39-1.51)。
临床怎么用
- 对ASCVD患者检测脂蛋白(a)有助于识别复发风险持续升高者,尤其脂蛋白(a)≥180 nmol/L者。
- 高强度降LDL-C治疗(如PCSK9抑制剂)可能部分减轻脂蛋白(a)≥180 nmol/L相关的不良影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Higher levels of lipoprotein(a) drive increasing risk of atherosclerotic cardiovascular disease (ASCVD) in otherwise healthy individuals regardless of sex and race/ethnicity. This study aimed to evaluate whether this is also true for recurrent ASCVD, and whether LDL cholesterol-lowering therapy possibly mitigates such a relationship. METHODS: In US medical claims between 2012 and 2022 for 340 million individuals, 273 770 had diagnosed ASCVD and lipoprotein(a) measured in nmol/L. These women (n = 117 269; 43%) and men (n = 156 501; 57%) included Black (n = 22 451; 8%), Hispanic (n = 24 606; 9%), and White (n = 161 165; 59%) individuals. RESULTS: Lipoprotein(a) levels were higher in women vs men and in Black vs Hispanic and White individuals. During a median follow-up of 5.4 years, 41 687 individuals (15%) experienced recurrent ASCVD. Higher lipoprotein(a) levels were associated with continuously increasing risk of recurrent ASCVD. Compared to individuals with lipoprotein(a) < 15 nmol/L, the adjusted hazard ratios for recurrent ASCVD events were 1.04 (95% confidence interval 1.01-1.07) for 15-79 nmol/L, 1.15 (1.12-1.19) for 80-179 nmol/L, 1.29 (1.25-1.33) for 180-299 nmol/L, and 1.45 (1.39-1.51) for ≥300 nmol/L. Results were similar for individual ASCVD components, and in sex, race/ethnicity, baseline ASCVD, and diabetes subgroups; however, high impact LDL cholesterol-lowering therapy possibly mitigates the deleterious effect of lipoprotein(a) ≥ 180 nmol/L, most pronounced in those on PCSK9 inhibitors. Interaction on recurrent ASCVD events between lipoprotein(a) categories and sex, race/ethnicity, baseline ASCVD, diabetes, and impact of LDL cholesterol-lowering therapy use had P-values of .61, .06, .33, .91, and 2 × 10-8, respectively. CONCLUSIONS: In 273 770 individuals with ASCVD, higher lipoprotein(a) levels were associated with continuously increasing risk of recurrent ASCVD events regardless of sex and race/ethnicity that may have been partially mitigated by high impact LDL cholesterol-lowering therapy.
引用
- MacDougall DE, Tybjærg-Hansen A, Knowles JW, et al. Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. Eur Heart J. 2025. PMID: 40331569. doi:10.1093/eurheartj/ehaf297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。